New RSV vaccine trial aims to protect vulnerable transplant patients
NCT ID NCT06593210
First seen Jan 10, 2026 · Last updated May 08, 2026 · Updated 19 times
Summary
This study tests a non-live RSV vaccine in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants will give blood samples and be monitored for side effects, infections, and transplant complications for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network
Toronto, Canada
Conditions
Explore the condition pages connected to this study.